Reference12 articles.
1. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps;Bhattacharyya;Laryngoscope,2019
2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials;Bachert;Lancet,2019
3. Conjunctivitis in dupilumab clinical trials;Akinlade;Br J Dermatol,2019
4. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial;Bachert;J Allergy Clin Immunol,2017
5. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis;Gevaert;J Allergy Clin Immunol,2011
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献